46 results about "Hepatitis b surface antigen" patented technology

The invention relates to the technical field of biological medicines, in particular to a vaccine for treating or preventing hepatitis B virus infection. The vaccine comprises a hepatitis B surface antigen and a composite adjuvant, wherein the composite adjuvant is prepared from CpG oligodeoxynucleotide and saponin QS-21, and the composite adjuvant is prepared from CpG oligodeoxynucleotide and saponin QS-21; the nucleotide sequence of the CpG oligodeoxynucleotide is as shown in SEQ ID NO. 1. According to the vaccine provided by the invention, an HBsAg antibody can be generated in a normal mouse body, and HBV in an HBV-carrier mouse can be effectively eliminated, so that the vaccine has the effect of treating or preventing hepatitis B virus infection. According to the vaccine provided by the invention, two adjuvants, namely CpG oligodeoxynucleotide and saponin QS-21, are adopted, so that the vaccine can be used for synergistically activating an immune effect, enhancing the activation of B cells and permanently transforming into plasma cells, and meanwhile, the vaccine can be used for resisting immune tolerance of T cells, realizing the removal of hepatitis B viruses and realizing functional cure of clinical hepatitis B treatment.

The invention discloses an application of a combination of entecavir, an ASO drug, an mRNA therapeutic vaccine and / or interferon in preparation of drugs for treating chronic hepatitis B. Entecavir and interferon have an antiviral effect, the ASO drug reduces hepatitis B surface antigen titer, and the mRNA therapeutic vaccine is high in immunization speed, so that the entecavir, ASO drug, mRNA therapeutic vaccine and / or interferon combination can inhibit virus replication, and can be used for treating chronic hepatitis B. The composition strikes hepatitis B virus from multiple angles and multiple levels, achieves a good, lasting and non-rebound antiviral effect, and can cure hepatitis B to a certain extent.

The invention belongs to the field of biological medicines, and particularly relates to an antigen-antibody compound for enhancing immune response of hepatitis B patients as well as a preparation method and application of the antigen-antibody compound. The antigen-antibody compound preparation prepared from the HBsAg and the anti-HBsAg monoclonal antibody is superior to an antigen-antibody compound preparation prepared from a polyclonal antibody in the aspect of continuously inducing the immune response of a chronic hepatitis B patient, and an antigen-antibody compound for inducing the immune response of the hepatitis B patient is developed for the first time; in the compound, the hepatitis B surface antigen is combined with the anti-HBsAg monoclonal antibody, and the compound formed by the hepatitis B surface antigen and the anti-HBsAg monoclonal antibody in a certain mass ratio can induce immune response of chronic hepatitis B patients and can also prevent and / or treat chronic hepatitis B.

Disclosed are antibodies to anti-hepatitis B surface antigen (HBsAg) (especially humanized antibodies), nucleic acid molecules encoding same, methods for preparing same, and pharmaceutical compositions containing same. The antibodies have higher affinity for HBsAg at neutral pH than at acidic pH, thereby significantly enhancing the virus clearance efficiency and prolonging the virus inhibition time. The antibodies and the pharmaceutical compositions can be used for preventing and / or treating HBV infections or diseases related to HBV infections (e.g., hepatitis B), for neutralizing the virulence of HBV in a subject (e.g., a human), for reducing the serum level of HBV DNA and / or HBsAg in the body of the subject, or for activating the humoral immune response of the subject (e.g., a chronic HBV infected or chronic hepatitis B patient) against HBV.

Provided herein are methods of detecting sources of hepatitis B virus (HBV) surface antigens (HbsAgs) in samples. Some exemplary embodiments include amplifying HBV transcript nucleic acids in or from a sample and quantifying an amount of HBV transcript nucleic acids transcribed from HBV cccDNA and an amount of HBV transcript nucleic acids transcribed from the HBV iDNA. Related systems and other aspects are also provided.

A preparation method for and the use of an aluminum hydroxide oxide nano-adjuvant based on calcium and silicon doping. The particle morphology of the AlOOH adjuvant is a 50-800 nm nano-particle, wherein silicon or calcium is doped in AlOOH crystal lattices, and the molar ratio of calcium or silicon to aluminum is 0.01-100:1. The preparation method comprises: synthesizing AlOOH by using an Al source, doping Ca or Si in a reaction solution by using a calcium source or a silicon source, precipitating Al(OH)3 and a dopant by adding an alkaline solution, and preparing a Ca- or Si-doped AlOOH adjuvant by means of a hydrothermal synthesis method. In a hepatitis B surface antigen and varicella-zoster virus glycoprotein E antigen model, the calcium- or silicon-doped AlOOH nano-adjuvant can simultaneously induce efficient humoral immunity and cellular immunity by means of in-vivo experiment verification of mice.

The present invention provides a multi-wavelength-based HBsAg detection method, including: detecting the light absorption value of a sample to be tested for HBsAg by a sandwich ELISA method using a multi-wavelength microplate reader to obtain the light absorption data of the sample to be tested for HBsAg at multiple wavelengths; determining the OD value of the sample, the OD value of the negative control, and the OD value of the positive control at dual wavelengths based on the light absorption data at wavelengths of 450 nm and 630 nm; determining whether the first detection result is valid within the preset concentration range of HBsAg based on the OD value of the negative control and the OD value of the positive control; if the first detection result is invalid within the preset concentration range of HBsAg, determining the second detection result of the sample to be tested for HBsAg based on the mapping relationship between the light absorption data at multiple wavelengths and the detection result of chemiluminescence method. The present invention improves the sensitivity, accuracy, and reliability of hepatitis B surface antigen detection at low concentrations.

The application discloses an LDH-based vaccine adjuvant and a preparation method and application thereof, and belongs to the technical field of aluminum adjuvant preparation of vaccines, and the preparation method comprises the following steps: mixing at least one of soluble magnesium salt, soluble zinc salt, soluble manganese salt and soluble calcium salt with soluble aluminum salt, and then performing a co-precipitation reaction with a sodium hydroxide aqueous solution in a colloid mill device, and performing crystallization to obtain LDH nanosheets; dispersing the LDH nanosheets in a PBS solution, adding a hepatitis B surface antigen molecule drug, uniformly mixing, and then performing centrifugation to obtain the LDH-based vaccine adjuvant. The LDH-based vaccine adjuvant can significantly promote the maturation of DC cells and the activation of T cells, and the total IgG level reflects the overall humoral immune response intensity of the body to vaccines or pathogens; the LDH-based vaccine adjuvant forms a "storage library" at an injection site to store antigens and slowly release the antigens, and the purpose of long-time continuous stimulation of the immune system in the body is achieved.

The present invention relates to the use of ciprofibrate in the preparation of a drug for anti-hepatitis B virus, belonging to the field of biomedical technology. The present invention provides the use of ciprofibrate in the preparation of a drug for anti-hepatitis B virus. Ciprofibrate reduces the expression levels of hepatitis B surface antigen HBsAg, hepatitis B e antigen HBeAg, and hepatitis B core antigen HBcAg in human primary cells infected with hepatitis B virus, inhibits hepatitis B virus from infecting cells, inhibits the proliferation and replication of hepatitis B virus, can protect neonatal hepatocytes from being reinfected, has an anti-hepatitis B virus effect, and thus prevents and treats diseases caused by hepatitis B virus. Ciprofibrate, as a lipid-regulating drug, has minor side effects, does not require subcutaneous injection, and has high patient compliance.

The invention discloses a bipyrimidine heterocyclic compound and a preparation method and application thereof, the bipyrimidine heterocyclic compound has a structure as shown in a formula (I), and the invention also provides a pharmaceutical composition containing the compound or a stereoisomer, a medicinal salt, a hydrate, a solvate or a crystal thereof. The invention also discloses application of the compounds in preparation of drugs for treating hepatitis B virus infection, and particularly the compounds can be used as PAPD5 / 7 enzyme inhibitors and hepatitis B RNA non-stabilizers for treating hepatitis B viruses. The compound provided by the invention has the characteristics that the concentration of hepatitis B surface antigen and hepatitis B DNA and RNA can be remarkably reduced, and the probability of functional healing of hepatitis B can be remarkably improved by clinically combining with nucleoside drugs, oligonucleotide drugs / PD-L1 compounds and the like.

Provided are affinity ligands that bind to Hepatitis B surface antigen (HBsAg), affinity resins comprising the HBsAg-binding ligands, and related compositions and methods for the isolation and / or purification of HBsAg.

The invention relates to a composition comprising a polypeptide comprising, or consisting of, the amino acid sequence of SEQ ID) NO: 1, or a sequence having at least 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to SEQ ID NO: 1 (R21), wherein said polypeptide is in the form of a virus-like particle (VLP), wherein said particle comprises less than 10% free hepatitis B surface antigen protein, for use in the immunisation of a human subject susceptible to Plasmodium falciparum infection, characterised in that said composition is administered in a dosage regimen of at least one dose of 1 μg to 20 μg R21 per administration for a subject at least 18 years old, or at least one dose of 0.5 μg to 10 μg R21 per administration for a subject less than 18 years old. The invention also relates to kits, methods and uses.

This invention belongs to the field of affinity membrane and bioseparation technology, and provides a cellulose-based affinity membrane for hepatitis B virus (HBV), its preparation method, and its application. The affinity membrane consists of a base membrane and an affinity ligand immobilized on the base membrane. The base membrane is a carboxylated cellulose filter membrane or a carboxylated modified cellulose filter membrane. The affinity ligand is a biomolecule that specifically recognizes HBV surface antigen. The carboxyl groups of the base membrane and the amino groups of the affinity ligand are linked by amide bonds. Unreacted carboxyl groups on the base membrane are blocked by a blocking reagent. The carboxyl content of the base membrane is 400-1000 μmol / g, the pore size is 400-1000 nm, and the porosity is 30%-60%. The application refers to the use of the above-mentioned affinity membrane in the specific clearance of HBV from HBV-positive plasma. This invention can achieve efficient and specific clearance of HBV from plasma, maximally preserving the activity and function of normal plasma components, and improving the feasibility of industrial application.

A combination comprising a tricycle compound and use thereof in the preparation of a medicament for treating HBV. The combination is a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof and any one drug in the following groups a-c: a. a hepatitis B surface antigen inhibitor, b. a reverse transcriptase inhibitor, and c. a hepatitis B surface antigen inhibitor and a reverse transcriptase inhibitor.

The present invention relates to: a conjugate in which a receptor-binding domain (RBD) of coronavirus and a hepatitis B surface antigen (HBsAg) are linked; virus-like particles including the conjugate; and a coronavirus vaccine composition containing the conjugate and / or virus-like particles.

The invention provides application of a BTLA inhibitor in preparation of a medicine for preventing and / or treating chronic hepatitis B, and belongs to the technical field of biological medicine. Research finds that antagonistic B and T lymphocyte attenuation factors (BTLA) can promote removal of hepatitis B surface antigen (HBsAg), reduce the expression level of HBeAg, promote activation and proliferation of T cells and enhance host immune response, so that the purpose of preventing and / or treating chronic hepatitis B is achieved, and functional cure of chronic hepatitis B (CHB) is achieved. The invention provides more choices for medicines for clinically preventing and / or treating chronic hepatitis B.

The application belongs to the technical field of pharmaceutical chemistry, and discloses a compound for inhibiting hepatitis B surface antigen and application thereof. It is proved through research that the recombinant plasmid S-HiBiT constructed can characterize the expression and secretion of HBs, and can be used for screening the compound for inhibiting HBs, and a cell model for screening anti-HBV drugs targeting HBsAg, i.e. HepG2-PB-S-HiBiT stable expression cell line. It is verified through experiments that the model is particularly suitable for high-throughput screening of compounds. Compound 1 and compound 3 capable of inhibiting HBsAg are found through screening of a compound library by using the model, the drug has the potential to be further developed into a hepatitis B treatment candidate drug, and a new drug is provided for the treatment of hepatitis B.

An oral vaccine for Hepatitis B is disclosed. The oral vaccine for Hepatitis B includes a delivery platform including Arthrospira platensis with a plurality of host genomes and a plurality of Hepatitis B surface antigen delivery vectors coupled to the plurality of host genomes. Each Hepatitis B surface antigen delivery vector of the plurality of Hepatitis B surface antigen delivery vectors has a nucleotide sequence identical to nucleotide sequence of SEQ ID NO. 2. Each respective Hepatitis B surface antigen delivery vector of the plurality of Hepatitis B surface antigen delivery vectors includes at least one surface antigen of Hepatitis B with a weight ratio of the delivery platform to the at least one surface antigen of Hepatitis B in a range of 1: 10-4 to 1: 2x10- 3 (delivery platform: at least one surface antigen of Hepatitis B).

The present invention provides a multi-wavelength-based HBsAg detection method, including: detecting the optical absorption value of a sample to be detected for HBsAg by a sandwich immunoassay using a multi-wavelength microplate reader to obtain the optical absorption data of the sample to be detected for HBsAg at multiple wavelengths; determining the OD value of the sample, the OD value of the negative control, and the OD value of the positive control at two wavelengths based on the optical absorption data at 450 nm and 630 nm wavelengths; determining whether the first detection result is valid within the preset concentration range of HBsAg based on the OD value of the negative control and the OD value of the positive control; if the first detection result is invalid within the preset concentration range of HBsAg, determining the second detection result of the sample to be detected for HBsAg based on the mapping relationship between the optical absorption data at multiple wavelengths and the detection result of chemiluminescence method. The present invention improves the sensitivity, accuracy, and reliability of the detection of hepatitis B surface antigen at low concentrations.

The application discloses a hepatitis B surface antigen specific B cell receptor gene knock-in mouse model, and establishes a hepatitis B virus surface antigen (HBsAg) specific B cell receptor (BCR) gene knock-in mouse model, wherein 70-90% of B cells of the mouse can specifically recognize HBsAg, and differentiate into germinal center B cells and plasma cells. Therefore, the model can be used for basic research on hepatitis B antiviral humoral immune response and tolerance mechanism, and can also be used for application research on development of drugs and vaccines for breaking HBsAg immune tolerance. In summary, the establishment of the model lays a solid foundation for development of a functional cure immune means for hepatitis B.

The invention provides a multi-wavelength-based HBsAg detection method, which comprises the following steps: carrying out light absorption value detection on an HBsAg sample to be detected by a double-antibody sandwich method through a multi-wavelength microplate reader to obtain light absorption data of the HBsAg sample to be detected under multiple wavelengths; based on the light absorption data under the wavelength of 450 nm and the wavelength of 630 nm, determining a sample OD value, a negative control OD value and a positive control OD value under dual wavelengths; based on the negative control OD value and the positive control OD value, determining whether the first detection result is effective in a preset concentration range of HBsAg; and if the first detection result is invalid in the preset concentration range of HBsAg, determining a second detection result of the HBsAg sample to be detected based on a mapping relationship between the light absorption data under multiple wavelengths and a chemiluminescence method detection result. According to the invention, the sensitivity, accuracy and credibility of low-concentration hepatitis B surface antigen detection are improved.

There is provided a method of curing chronic hepatitis B infection in a human, the method comprising administering to a subject in need thereof an effective amount of one or both of an exogenous anti-HBs antibody or an anti-HBs antibody producing carrier, the present invention relates to a method for reducing cellular and blood hepatitis B surface antigen (HBsAg) by providing continuously increased levels of anti-HBs antibodies in the subject.

The present invention relates to hepatitis B immune regimens and compositions. The present invention provides a method of treating chronic hepatitis B infection (CHB) in a human comprising the steps of: a) administering to the human a composition comprising a replication-deficient chimpanzee adenovirus (ChAd) vector, the replication-deficient chimpanzee adenovirus (ChAd) vector comprises a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); b) administering to the human a composition comprising a modified vaccinia virus Ankara (MVA) vector, the modified vaccinia virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); and c) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), a recombinant hepatitis B virus core antigen (HBc) and an adjuvant.

The invention discloses matrine type alkaloid SA as well as a preparation method and application thereof, and belongs to the field of traditional Chinese medicine preparation. The matrine type alkaloid with a new structure is extracted from sophora moorcroftiana, and cell experiments find that the matrine type alkaloid not only has the effect of resisting hepatitis B virus (HBV), but also has the inhibitory effect on hepatitis B surface antigen (HBsAg) superior to that of matrine and oxymatrine of the same kind, and also superior to that of lamivudine. Therefore, the matrine type alkaloid can be used for preparing the medicine for treating or preventing hepatitis B virus (HBV) infection.

The present application relates to the technical field of immunological detection, in particular to hepatitis B PreS1 antigen and its preparation method and application. The present application first selects an active PreS1 polypeptide sequence, which is coupled to a hepatitis B surface antigen HBsAg molecule through a crosslinking agent to obtain a hepatitis B PreS1 antigen having both hepatitis B surface antigen activity and PreS1 antigen activity, which can be used as a calibrator and positive control in a hepatitis B PreS1 antigen detection kit. The kit uses anti-PreS1 antibody as coating and anti-HBsAg antibody as enzyme label. The artificial coupled hepatitis B PreS1 antigen prepared by the present application can effectively replace the currently used PreS1 real positive sample on the market, has no biological safety risk, stable source, and various indexes such as reactivity, vehicle stability and thermal stability, which are all better than those of the real positive sample, and has high innovation and applicability.

There is provided a method of treating chronic hepatitis B infection (CHB) and / or chronic hepatitis D infection (CHD) in a human, comprising the steps of:a) administering to the human a composition comprising an antisense oligonucleotide (ASO) 10 to 30 nucleosides in length, targeted to a HBV nucleic acid (an HBV ASO);b) administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc);c) administering to the human a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); andd) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B virus core antigen (HBc) and an adjuvant.

The invention provides a modified immune cell which comprises a T cell receptor (TCR) capable of specifically targeting hepatitis B surface antigen (HBsAg) and a chimeric transformation receptor, the chimeric transformation receptor adopts an intracellular activation signal domain of a co-stimulatory molecule to replace an intracellular suppression signal domain of an immunosuppression receptor, and the chimeric transformation receptor can specifically target the hepatitis B surface antigen (HBsAg). An inhibitory signal induced by binding of an immunosuppressive receptor and a ligand is converted into an activation signal. The invention also provides a nucleic acid molecule for coding the TCR and / or coding the chimeric transformation receptor, a carrier containing the nucleic acid molecule, and application of the nucleic acid molecule in drugs for preventing and / or treating HBV infection and related diseases thereof.

The invention discloses a nano antibody targeting a hepatitis B surface antigen and application of the nano antibody. The nano antibody has an amino acid sequence as shown in SEQ ID NO: 1-5, and has high affinity to HBsAg. The nano antibody not only can effectively neutralize hepatitis B virus, but also can enter cells to realize'multi-link and all-directional 'inhibition of virus life cycle, including inhibition of virus RNA transcription, protein expression, nucleocapsid assembly, DNA replication and particle secretion, and can significantly down-regulate HNF4alpha, Sp1 and other key transcription factors in host hepatocytes. The antibody can be efficiently expressed in a prokaryotic or eukaryotic system. The PEGylated derivative (such as Nb1-PEG40) can prolong the half-life period, and shows stronger effects of clearing serum HBsAg and inhibiting liver virus replication in an HBV infected mouse model. The invention provides a new strategy and drug candidate for hepatitis B treatment.

The invention relates to a passive active oxygen generating device which is characterized by comprising a shell, a substrate and a reaction film which are arranged in sequence. Visible light in the environment enters the reaction film and is absorbed by the reaction film, a large number of vacancies and electrons are generated, and the vacancies and electrons react with water or oxygen molecules in the surrounding environment to generate active oxygen. The active oxygen is a broad-spectrum bactericide, can kill bacterial propagules, bacterial spores, viruses and fungi, also has a good killing effect on protozoa and oocysts thereof, and also can destroy bacterial toxins, hepatitis B surface antigens and the like. The device can be applied to sterilization and disinfection of object surfaces, air and the like, and has the advantages of no need of additional energy sources, high efficiency, lasting performance and the like.

This invention discloses a non-invasive systemic assessment method and system for predicting the transformation of follicular lymphoma. The method includes the following steps: S1, obtaining four characteristics of the subject: peripheral blood hepatitis B surface antigen (HBsAg), neutrophil-to-lymphocyte ratio (NLR), serum lactate dehydrogenase (LDH), and PET-CT reporting maximum standardized uptake (SUVmax); S2, determining the weight of each characteristic based on its importance, with the weights from high to low being HBsAg, LDH, NLR, and SUVmax, and converting each characteristic into a risk score of 0-3 points using a unique fixed node; S3, weighted summing of the scores of the four characteristics to obtain a total score S, establishing a correspondence between the total score and transformation, constructing a web-based calculator and transformation scoring system, and outputting the individual transformation probability prediction result. By embedding the four conventional indicators (HBsAg, NLR, LDH, and SUVmax) selected by LASSO and Boruta into a lightweight CatBoost model, the transformation probability can be output, realizing a non-invasive assessment of the histological transformation risk of follicular lymphoma at initial diagnosis.